Novigenix secures EUR 1.8 million to scale precision oncology platform
Life sciences
9 April 2025
Based at Lausanne’s Biopôle campus, Novigenix is contributing to the EU-funded BRECISE project with its predictive liquid biopsy technology. | © Novigenix
Medtech start-up Novigenix has received EUR 1.8 million from the EU’s Innovative Health Initiative to support the industrialization of its AI-driven liquid biopsy platform as part of a major international cancer research collaboration.
Novigenix, a company based at Biopôle in Lausanne and specializing in AI-powered precision oncology, has been awarded EUR 1.8 million through the European Union’s Innovative Health Initiative (IHI). The funding supports its participation in BRECISE, a pan-European research consortium aiming to transform cancer diagnostics and treatment through the integration of next-generation sequencing (NGS) and artificial intelligence.
BRECISE was officially launched in Madrid during the European Association of Urology Congress and brings together partners from academia, clinical institutions, and industry. Co-funded under Horizon Europe, the initiative focuses on accelerating the validation of biomarker models to support more personalized and effective cancer care, with a particular focus on prostate and bladder cancers.
Strengthening Europe’s innovation ecosystem in cancer care
As part of the project, Novigenix will advance its LITOSeek platform, a liquid biopsy technology that combines transcriptomic and genomic data derived from blood samples. Using AI-based analytics, LITOSeek aims to improve the prediction of patient response to immunotherapies, identify potential adverse effects, and support biopharma companies in optimizing patient selection for clinical trials. These capabilities could lead to more effective treatments while reducing complications and inefficiencies in drug development.
The grant will allow Novigenix to move from research-scale development toward industrialization, ensuring the platform meets the standards required for clinical adoption across European healthcare systems. The company’s contribution reflects over a decade of expertise in multi-omics data integration and AI-driven diagnostics.
By participating in BRECISE, Novigenix reinforces Western Switzerland’s presence in European innovation ecosystems and underlines the strategic importance of cross-border collaboration in advancing precision medicine. The project demonstrates how emerging technologies can bring tangible improvements to patient care and contribute to the evolution of oncology across Europe.
